Astragaloside IV Improves Bleomycin-Induced Pulmonary Fibrosis in Rats by Attenuating Extracellular Matrix Deposition
Pulmonary fibrosis is a devastating lung disorder with mysterious pathogenesis and limited treatment options. It is well-recognized that the uncontrolled proliferation of lung fibroblasts and differentiation of fibroblasts into myofibroblasts excessively produce extracellular matrix (ECM) proteins w...
Main Authors: | Liu-Cheng Li, Liang Xu, Yan Hu, Wen-Jie Cui, Wen-Hui Cui, Wen-Cheng Zhou, Lian-Di Kan |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2017-08-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fphar.2017.00513/full |
Similar Items
-
Integrating Network Pharmacology and Experimental Validation to Explore the Pharmacological Mechanism of Astragaloside IV in Treating Bleomycin-Induced Pulmonary Fibrosis
by: Yuan S, et al.
Published: (2023-04-01) -
Astragaloside IV Ameliorates Isoprenaline-Induced Cardiac Fibrosis in Mice via Modulating Gut Microbiota and Fecal Metabolites
by: Xu-Qin Du, et al.
Published: (2022-05-01) -
Astragaloside IV, as a potential anticancer agent
by: Dongqin Xia, et al.
Published: (2023-02-01) -
Astragaloside IV Ameliorates Myocardial Infarction Induced Apoptosis and Restores Cardiac Function
by: Chuang Sun, et al.
Published: (2021-07-01) -
Effect of astragaloside IV on indoxyl sulfate-induced kidney injury in mice via attenuation of oxidative stress
by: Chunlan Ji, et al.
Published: (2018-09-01)